SAN DIEGO, June 25, 2021 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical enterprise targeted on the discovery and improvement of progressive medications targeting microRNAs (the “Corporation” or “Regulus”), now introduced the presentation of supplemental information from the initially cohort of sufferers in the Company’s Section 1b medical demo of RGLS4326 for the treatment of autosomal dominant polycystic kidney illness (ADPKD), as properly as new preclinical info from applicable animal products of the disorder. The E-poster presentation, titled “Preclinical Evaluation and Final results from the Initially Cohort of Phase 1b Medical Demo of RGLS4326 for the Procedure of
WALTHAM, Mass.–(Enterprise WIRE)–Xilio Therapeutics, a biotechnology organization acquiring tumor-selective immuno-oncology therapies for patients with most cancers, today announced that the U.S. Food stuff and Drug Administration has recognized its Investigational New Drug application (IND) to examine its checkpoint inhibitor product or service prospect, XTX101, as a potential treatment for people with sound tumors. XTX101 is a tumor-selective anti-CTLA-4 monoclonal antibody created to improve upon the therapeutic index of existing anti-CTLA-4 therapies by conquering their historical potency and tolerability limitations.
“This initial IND acceptance for Xilio represents a significant milestone for us as we transition to a clinical-phase